

RECEIVED  
CENTRAL FAX CENTER

018

OCT 30 2006

Express Mail Label:

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): <b>BAZAN, Fernando J.</b>	Group Art Unit: <b>1644</b>
Application No.: <b>10/601,105</b>	Examiner: <b>Jalla Sanjoo</b>
Filed: <b>06/20/2003</b>	
For: <b>Mammalian Cytokines; Related Reagents and Methods</b>	Attorney Docket No.: <b>DX0903K1BUS</b>

X

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
 P.O. Box 1450  
 Alexandria, VA 22313-1450  
 Mail Stop: **RCE**

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. §1.56, it is requested that the documents listed on the accompanying Forms PTO/SB.08a and 08b be considered and made record in the above-identified patent application. Other than cited U.S. patents and published patent applications, copy(ies) of these documents  are enclosed  were filed in related U.S. Application No(s) \_\_\_\_\_ filed \_\_\_\_\_, respectively. Since the Examiner is believed to have ready access to the cited U.S. patents and published patent applications, copies of these documents are not herewith transmitted, but will be provided upon request.

(b) No fee is believed due because:

- This Information Disclosure Statement is being submitted concurrently with the filing of the above-identified application; or
- This Information Disclosure Statement is being submitted within three (3) months of the filing date of the above-identified application, or
- This Information Disclosure Statement is being submitted concurrently with a Request for Continued Examination (RCE), or
- This Information Disclosure Statement is being submitted prior to the mailing of a first Office Action on the merits.

(c)  This Information Disclosure Statement is being submitted before the mailing date of any final action, notice of allowance or an action that otherwise closes prosecution; and

- Each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or
- No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement; or

70344\_1.DOC

**BEST AVAILABLE COPY**

Serial No. 10/601,105  
October 30, 2006  
Page 2 of 2

The Commissioner is hereby authorized to charge the requisite fee listed on the attached Fee Transmittal Sheet.

(d)  This Information Disclosure Statement is being submitted on or before the payment of the issue fee; and


Each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or

No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement; and

The Commissioner is hereby authorized to charge the requisite fee listed on the attached Fee Transmittal Sheet.

The Commissioner is hereby authorized to charge any additional fees which may be required for this Information Disclosure Statement, or credit any overpayment to Deposit Account No. 19-0365.

Respectfully submitted,  
SCHERING-PLOUGH CORPORATION



Dated: October 30, 2006  
SCHERING-PLOUGH CORPORATION  
Patent Department, K-6-1, 1990  
2000 Galloping Hill Road  
Kenilworth, NJ 07033-0530  
Facsimile No.: (908) 298-5388

By:

Name: Grant E. Reed  
Reg. No.: 41,264  
Attorney of Record  
Telephone No.: (908) 298-5067

70344\_1.DOC

**BEST AVAILABLE COPY**

Express Mail Label:

PTO/SB/08 (08-03)

Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1895, no persons are required to respond to collection of information unless it contains a valid OMB control number.

Complete if Known

Substitute for form 1449A/PTO		Application Number	10/601,105
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Filing Date	06/20/2003
		First Named Inventor	Bazan, J. Fernando
		Art Unit	1644
		Examiner Name	Jalila Sanjoo
		Attorney Docket Number	DX0909K1B US
Sheet	1	of	1

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US 2003/0099947 A1	05-29-2003	Bazan et al.	

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Number, Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		Friend, et al., "A Thymic Stromal Cell Line Supports In Vitro Development of Surface IgM+ B Cells and Produces a Novel Growth Factor Affecting B and T Lineage Cells", <i>Experimental Hematology</i> , 22: 321-328 (March 1994).	
		Pending Claims for U.S. Patent Application Serial No. 09/963,347 (published as US 2003/0099947 A1); Bazan, et al., "Mammalian Cytokines; Related Reagents and Methods" (1 page).	
		International Search Report for application no. PCT/US99/20871 (6 pages).	
		XP-002131157, "ak28a11.s1 Soares_testis_NHT Homo sapiens cDNA clone IMAGE: 1407260 3', mRNA sequence," AA889581.1, " displaying "06-APR-1998 (Rel. 55, Created)" and "06-JAN-1999 (Rel. 58, Last updated Version 2)" (2 pages).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 801.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached, as indicated on the document under WIPO Standard ST.16 if possible. This collection of information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

70341

PAGE 20/37 \* RCVD AT 10/30/2006 12:27:29 PM [Eastern Standard Time] \* SVR:USPTO-EFXRF-6/36 \* DMS:2738300 \* CSID:908 298 5405 \* DURATION (mm:ss):05:16